Bringing the fundamentals into focus…
Back to NovaBridge Biosciences
How NovaBridge Biosciences stacks up
NBP · against 116 other Healthcare companies of similar size
Overall
40/ 100
Below the middle of the pack.
Ranked #62 of 117 · scores higher than 47% of peers
Bars: peers in each 10-point band of the overall score23 peers with an overall score of 40–49, including NBP · Click a bar to see the companies
The four scores behind it
Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)Ranking by overall score
Top 5 and the companies ranked around NBP| Rank | Company | Market cap | Overall | Valuation | Growth | Profitability | Risk |
|---|---|---|---|---|---|---|---|
| 1 | 592M ILS (≈$160M) | 84 | 99 | 99 | 96 | 1 / 2 | |
| 2 | 178.5B KRW (≈$129M) | 76 | 91 | 55 | 77 | 0 / 2 | |
| 2 | 6.5B TWD (≈$200M) | 76 | 83 | 78 | 56 | 0 / 2 | |
| 4 | 188M CHF (≈$216M) | 74 | 96 | 87 | 83 | 2 / 2 | |
| 5 | 1.1B HKD (≈$146M) | 72 | 99 | 53 | 80 | 1 / 2 | |
| 57 | 7.2B TWD (≈$224M) | 41 | 8 | 99 | 10 | 1 / 2 | |
| 57 | 207M USD | 41 | 8 | — | 17 | 0 / 2 | |
| 57 | 172M USD | 41 | 8 | 74 | 8 | 0 / 2 | |
| 62 | 131M CAD (≈$96M) | 40 | 82 | 22 | 33 | 2 / 2 | |
| 62 | 117M USD | 40 | 33 | — | 11 | 0 / 2 | |
| 64 | 1.5B CNY (≈$205M) | 39 | 37 | 12 | 38 | 0 / 2 | |
| 64 | 148M AUD (≈$98M) | 39 | 41 | — | 34 | 1 / 2 | |
| 66 | 110M USD | 38 | 33 | 97 | 22 | 2 / 2 | |
| 66 | 191M USD | 38 | 33 | 38 | 25 | 1 / 2 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score